Noven ADHD patch heads into Phase II

Noven Pharmaceuticals, a subsidiary of Hisamitsu Pharmaceutical, announced a Phase II trial of its d-Amphetamine Transdermal System (d-ATS), a skin patch designed to treat attention deficit hyperactivity disorder (ADHD) in children and adolescents.

The trial will recruit about 90 children and young people between 6 and 17 years old at 5 sites, and should complete mid-2013. According to Noven and its parent company Hisamitsu, there is currently no approved amphetamine-based transdermal treatment options available for ADHD. Noven's Daytrana methylphenidate transdermal system is available in the U.S.

ADHD, which affects an estimated 3% to 5% of children in the U.S., is often treated with stimulants, including amphetamines, but these can be open to abuse. Transdermal formulations are likely to be harder to abuse, and deliver a controlled dose over a longer period.

Noven came under fire from the FDA in 2011, for poor process validation and for running equipment unable to perform its intended function.

- read the press release

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.